HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS.

For all subjects, TP53wt status must be characterized by, at a minimum, no mutations noted in exons 5, 6, 7 and 8.

Two treatment arms will enroll subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity of HDM201+MBG453 (treatment arm 1) and HDM201+venetoclax (treatment arm 2).

• In the treatment arm 1, subjects will receive HDM201 in combination with MBG453.
• In the treatment arm 2, subjects will receive HDM201 in combination with venetoclax. Venetoclax dose will be gradually increased (ramp-up) over a period of 4 to 5 days to achieve the daily target dose tested that will be subsequently continued.

Upon the completion of the escalation part, MTD(s) and/or RD(s) of HDM201 in combination with MBG453 or venetoclax in AML and high-risk MDS subjects will be determined for each treatment arm.

Study Overview

• Status: Active, not recruiting
• Conditions: Acute Myeloid Leukemia (AML); High-risk Myelodysplastic Syndrome (MDS)
• Intervention / Treatment: Drug: HDM201; Biological: MBG453; Drug: Venetoclax

• Study Type: Interventional
• Enrollment (Actual): 52
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • Victoria
    • Melbourne, Victoria, Australia, 3004
      • Novartis Investigative Site
• Finland
  • Helsinki, Finland, FIN 00290
    • Novartis Investigative Site
• Germany
  • Heidelberg, Germany, 69120
    • Novartis Investigative Site
  • Wuerzburg, Germany, 97080
    • Novartis Investigative Site
• Italy
  • MI
    • Milano, MI, Italy, 20132
      • Novartis Investigative Site
  • RM
    • Roma, RM, Italy, 00161
      • Novartis Investigative Site
• Singapore
  • Singapore, Singapore, 119228
    • Novartis Investigative Site
• Spain
  • Madrid, Spain, 28041
    • Novartis Investigative Site
• United States
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Duke University Medical Center .

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Main Inclusion Criteria:

• Male or female patients ≥ 18 years of age at the date of ICF signature who present with one of the following:

  1. Relapsed/refractory AML following ≥1 prior therapies (but ≤3 prior therapies) who have relapsed or exhibited refractory disease (primary failure) and are deemed by the Investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established chemotherapy regimens for patients with AML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded)
  2. First line AML patient unfit for standard induction chemotherapy (includes both de novo and secondary AML), except in countries where approved therapies are available. Patients who are suitable for hematopoietic stem cell transplantation and willing to receive it are excluded.
  3. High-risk MDS patient (high and very high-risk groups according to rIPSS) who have failed hypomethylating agent therapy.
• ECOG performance status ≤ 1
• TP53wt tumor. At minimum exons 5, 6, 7 and 8 in the TP53 gene must be sequenced and determined to contain no mutations. The TP53 status must be obtained from a bone-marrow sample, collected no longer than 3 months before signing the main ICF.
• Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutional guidelines and be willing to undergo a bone marrow aspirate and/or biopsy at screening, during and at the end of therapy on this study. Exceptions may be considered after documented discussion with Novartis.

Main Exclusion Criteria:

Patients eligible for this study must not meet any of the following criteria:

• Prior combination treatment with compounds having the same mode of action:

  • mdm2 or mdm4 inhibitors combined with TIM-3 inhibitors (for patients enrolled in treatment arm1)
  • mdm2 or mdm4 inhibitors combined with Bcl-2 inhibitor (for patients enrolled in treatment arm2)
• History of severe hypersensitivity reactions to any ingredient of study drug(s) and other monoclonal antibodies (mAbs) and/or their excipients.
• Patients with acute promyelocytic leukemia with PML-RARA.
• Allogeneic stem cell transplant (HSCT) within last 6 months and/or active GvHD requiring systemic immunosuppressive therapy.
• GI disorders impacting absorption of oral HDM201 or venetoclax.
• Evidence of active bleeding or bleeding diathesis or major coagulopathy (including familial).
• Patients with active, known or suspected autoimmune disease (treatment arm 1 only).

Other eligibility criteria apply.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: treatment arm1: HDM201+MBG453; Phase Ib (escalation)	Drug: HDM201; Capsule; Biological: MBG453; LIVI (Liquid in vial) Concentrate for Solution for infusion
Experimental: treatment arm2: HDM201+venetoclax; Phase Ib (escalation)	Drug: HDM201; Capsule; Drug: Venetoclax; Tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety	Month 24 is assumed to be study end	at month 24
Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety	Month 24 is assumed to be study end	at month 24
Incidence of dose limiting toxicities (DLTs) of treatment	end of first cycle	at day 28
Frequency of dose interuptions	Month 24 is assumed to be study end	at month 24
Frequency of dose reductions	Month 24 is assumed to be study end	at month 24
Dose intensities	measured in mg/ day Month 24 is assumed to be study end	at month 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate (ORR)	Month 24 is assumed to be study end	at month 24
Best Overall Response (BOR)	Month 24 is assumed to be study end	at month 24
Event Free Survival (EFS) for AML (Cheson 2003) or Progression Free Survival (PFS) for MDS (Cheson 2006)	Month 24 is assumed to be study end	at month 24
Relapse Free Survival (RFS) for AML (Cheson 2003) or Time To Response (TTR) for MDS (Cheson 2006)	Month 24 is assumed to be study end	at month 24
Duration Of Response (DOR) for AML (Cheson 2003) and MDS (Cheson 2006)	Month 24 is assumed to be study end	at month 24
Presence of anti-MBG453 antibodies (treatment arm 1 HD201+MBG453)		at Day 1, Day 29 and at month 24
Concentration of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)		at Day 1, Day 2, Day 5, Day 6 and Day 29
Concentration of MBG453 (treatment arm 1 HDM201+MBG453)		at Day 1, Day 2, Day 8, Day 11, Day 15, Day 29 and at month 24
Concentration of venetoclax (treatment arm 2 HDM201+venetoclax)		at Day 1, Day 2, Day 3, Day 5, Day 6, Day 8, Day 9, Day 14, Day 15 and Day 29
PK parameter (AUC) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)	Cycle 6	at month 6
PK parameter (Cmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)	Cycle 6	at month 6
PK parameter (Tmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)	Cycle 6	at month 6
PK parameter (AUC) of MBG453 (treatment arm 1 HDM201+MBG453)	Cycle 6	at month 6
PK parameter (Cmax) of MBG453 (treatment arm 1 HDM201+MBG453)	Cycle 6	at month 6
PK parameter (Tmax) of MBG453 (treatment arm 1 HDM201+MBG453)	Cycle 6	at month 6
PK parameter (AUC) of venetoclax (treatment arm 2 HDM201+venetoclax)	Cycle 6	at month 6
PK parameter (Cmax) of venetoclax (treatment arm 2 HDM201+venetoclax)	Cycle 6	at month 6
PK parameter (Tmax) of venetoclax (treatment arm 2 HDM201+venetoclax)	Cycle 6	at month 6
Changes from baseline in GDF-15 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)		at Day 1 and Day 2
Changes from baseline in soluble TIM-3 (Treatment arm 1 HDM201+MBG453)	Cycle 6	at month 6

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): June 24, 2019
• Primary Completion (Estimated): March 15, 2024
• Study Completion (Estimated): March 15, 2024

Study Registration Dates

• First Submitted: May 2, 2019
• First Submitted That Met QC Criteria: May 6, 2019
• First Posted (Actual): May 7, 2019

Study Record Updates

• Last Update Posted (Estimated): January 23, 2024
• Last Update Submitted That Met QC Criteria: January 22, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: AML; MDS; TIM-3; Phase Ib; BHLRM; HDM201; TP53; MBG453; venetoclax; Bcl-2
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms by Histologic Type; Neoplasms; Disease; Bone Marrow Diseases; Hematologic Diseases; Precancerous Conditions; Syndrome; Myelodysplastic Syndromes; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia; Antineoplastic Agents; Venetoclax
• Other Study ID Numbers: CHDM201H12101C; 2018-004001-62 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No